Sunshine Biopharma Inc.
Sunshine Biopharma Inc.
09/11/2026 | Press release | Distributed by Public on 09/11/2026 15:00
Material Event (Form 8-K)
Item 8.01 Other Events.
As of the date of filing of this report, due to recent sales of Sunshine Biopharma Inc.'s (the "Company") common stock under the Company's previously disclosed at-the-market offering, the exercise price of the Company's outstanding Series B Warrants has been reduced to $1.2046, subject to further adjustment as set forth under the Series B Warrants.
Sunshine Biopharma Inc. published this content on September 11, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on September 11, 2026 at 21:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]